Lumos Pharma, based in Austin, Texas, is an early-stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency. It was founded in 2014 and is headquartered in Austin, Texas.
NewLink Genetics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immuno-oncology products aimed at enhancing the quality of life for cancer patients. Established over 15 years ago, the company is driven by a team of industry professionals and physician-scientists committed to advancing cancer treatments. Inspired by personal experiences with cancer, NewLink Genetics focuses on transformative research and development efforts to shift the paradigm of cancer care and improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.